Hospital-acquired Bacterial Pneumonia (HABP), Ventilator-associated Bacterial Pneumonia (VABP)
Conditions
Brief summary
The purpose of this study is to evaluate the efficacy and safety of HRS -8427 in patients with HABP/VABP.
Interventions
DRUGHRS-8427
HRS-8427 for injection.
DRUGMeropenem
Meropenem for injection.
Sponsors
Jiangsu HengRui Medicine Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Be able and willing to provide a written informed consent before the study, fully understand the study and be able to complete the study according to the protocol. 2. Male and female, ≥18 years. 3. Judged by the investigator, clinical diagnosis with HABP/VABP, expectation that the patients will require hospitalization and initial treatment with intravenous antibiotics. 4. All subjects must have a chest radiograph during screening or within 48h before randomization, showing the presence of new or progressive infiltrate(s) suggestive of bacterial pneumonia. 5. Women of childbearing potential must have a negative serum pregnancy test before the first dose and must be non-lactating. Fertile female subjects or male subjects whose partner is a fertile female agree to use highly effective form of contraception, with no plan of birth and sperm/ovum donation from the time of signing the informed consent form (ICF) till 14 days after the end of treatment.
Exclusion criteria
1. Subjects who have known or suspected community-acquired bacterial pneumonia (CABP), atypical pneumonia, or chemical pneumonia. 2. Subjects who have known or suspected pneumonia caused by mycoplasma, chlamydia, legionella, viruses, fungi or parasites. 3. HABP or VABP caused by obstruction. 4. Subjects who have received potentially effective antibiotic therapy for a continuous duration of more than 24 hours during the previous 72 hours prior to randomization. 5. Impairment of renal function with estimated glomerular filtration rate \< 15 mL/min, or receiving peritoneal dialysis/hemodialysis. 6. Subjects with significant laboratory abnormalities. 7. Other pulmonary diseases that may confound the assessment of efficacy or safety. 8. Known history of immune deficiency disease or receive immunocompromising treatment. 9. Severe cardiovascular and cerebrovascular diseases with clinical significance and unstable or uncontrolled condition. 10. Known or suspected central nervous system infections. 11. Patients received cancer treatment within 4 weeks before randomization or planned treatment during the study period. 12. Drug abuse within 1 year prior to randomization. 13. Judged by the Investigator, other reasons unsuitable for this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The all-cause mortality rate at Day 14. | From the first dose of the study drug to Day 14. |
Secondary
| Measure | Time frame |
|---|---|
| The total ventilation time. | Day 14 to Day 21. |
| The percentage of participants with microbiologic eradication at the early assessment (EA) period. | Day 4 after the start of the treatment. |
| The all-cause mortality rate at Day 28. | From the first dose of the study drug to Day 28. |
| The percentage of participants with microbiologic eradication at the test of cure (TOC) period. | Day 14 to 21. |
| The percentage of participants with microbiologic eradication at the follow-up (FU) period. | Day 21 to 28. |
| The percentage of participants with microbiologic eradication at the end of treatment (EOT) period. | Day 7 to 14. |
Countries
China
Contacts
Primary ContactXiaopeng Wang
Backup ContactYaru Wei
Outcome results
None listed